Last reviewed · How we verify
Desvenlafaxine Succinate Sustained-Release Formulation 25 mg
Desvenlafaxine Succinate Sustained-Release Formulation 25 mg, marketed by Pfizer, holds a significant position in the antidepressant market. The drug's key strength lies in its sustained-release formulation, which provides consistent therapeutic levels and enhances patient compliance. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Desvenlafaxine Succinate Sustained-Release Formulation 25 mg |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: